Physician profile
Codi Danielle Leggett
NPI 1033685748
$7,139.03
in general payments reported to CMS, 2019-2025
49 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,358 · 2022: $759 · 2023: $771 · 2024: $1,980 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.28 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $617.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $533.72 | 2021-2025 | |
| Lilly USA, LLC | $500.72 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Esperion Therapeutics, INC. | $463.98 | 2021-2025 | Nexletol |
| Amgen INC. | $387.92 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $316.05 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $313.82 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $313.74 | 2022-2025 | Wegovy, Ozempic |
| Medtronic, INC. | $261.98 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.70 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.20 | 2021-2025 | Jardiance |
| Dexcom, INC. | $244.75 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $231.67 | 2021-2025 | |
| Astellas Pharma US INC | $216.08 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $202.42 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Codi Leggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.